[go: up one dir, main page]

BG105108A - Инхибитори на фарнезил протеин трансфераза с in vivo чувствителност към радиоактивно облъчване - Google Patents

Инхибитори на фарнезил протеин трансфераза с in vivo чувствителност към радиоактивно облъчване

Info

Publication number
BG105108A
BG105108A BG105108A BG10510801A BG105108A BG 105108 A BG105108 A BG 105108A BG 105108 A BG105108 A BG 105108A BG 10510801 A BG10510801 A BG 10510801A BG 105108 A BG105108 A BG 105108A
Authority
BG
Bulgaria
Prior art keywords
protein transferase
transferase inhibitors
farnesyl protein
vivo
radiosensitizing properties
Prior art date
Application number
BG105108A
Other languages
English (en)
Other versions
BG64941B1 (bg
Inventor
Ginckel Robert Van
Wim Floren
David End
Walter Wouters
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of BG105108A publication Critical patent/BG105108A/bg
Publication of BG64941B1 publication Critical patent/BG64941B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Изобретението се отнася до инхибитори на фарнезилпротеин трансфераза, които са чувствителни към радиоактивно облъчване и са полезни при получаванетона фармацевтичен състав за приложение преди, по време на и след радиоактивно облъчване на тумори при лечението на ракови заболявания.
BG105108A 1998-07-06 2001-01-03 Инхибитори на фарнезил протеин трансфераза с in vivo чувствителност към радиосенсибилизиращи свойства BG64941B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98202257 1998-07-06
EP98204330 1998-12-18

Publications (2)

Publication Number Publication Date
BG105108A true BG105108A (bg) 2001-11-30
BG64941B1 BG64941B1 (bg) 2006-10-31

Family

ID=26150503

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105108A BG64941B1 (bg) 1998-07-06 2001-01-03 Инхибитори на фарнезил протеин трансфераза с in vivo чувствителност към радиосенсибилизиращи свойства

Country Status (30)

Country Link
US (1) US6545020B1 (bg)
EP (1) EP1094839B1 (bg)
JP (1) JP4530537B2 (bg)
KR (1) KR100591603B1 (bg)
CN (1) CN1152716C (bg)
AP (1) AP1599A (bg)
AT (1) ATE238811T1 (bg)
AU (1) AU762423B2 (bg)
BG (1) BG64941B1 (bg)
BR (1) BR9911861A (bg)
CA (1) CA2336624C (bg)
CZ (1) CZ300968B6 (bg)
DE (1) DE69907461T2 (bg)
DK (1) DK1094839T3 (bg)
EA (1) EA003877B1 (bg)
EE (1) EE04582B1 (bg)
ES (1) ES2199579T3 (bg)
HR (1) HRP20000903A2 (bg)
HU (1) HU229076B1 (bg)
ID (1) ID26987A (bg)
IL (2) IL140721A0 (bg)
MY (1) MY126519A (bg)
NO (1) NO328178B1 (bg)
PL (1) PL193464B1 (bg)
PT (1) PT1094839E (bg)
SI (1) SI1094839T1 (bg)
SK (1) SK284723B6 (bg)
TR (1) TR200003879T2 (bg)
TW (1) TW586937B (bg)
WO (1) WO2000001411A1 (bg)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20000904A2 (en) 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
PL193464B1 (pl) 1998-07-06 2007-02-28 Janssen Pharmaceutica Nv Zastosowanie inhibitora białkowej transferazy farnezylowej
US20030027839A1 (en) * 2000-02-04 2003-02-06 Palmer Peter Albert Farnesyl protein transferase inhiitors for treating breast cancer
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
AU2001293826A1 (en) 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
JP4974437B2 (ja) 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−［（置換フェニル）メチル］−キノリンおよびキナゾリン誘導体
US7196094B2 (en) 2000-09-25 2007-03-27 Janssen Pharmaceutica, N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
EP1322644A1 (en) 2000-09-25 2003-07-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
JP4348080B2 (ja) 2000-11-21 2009-10-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害するベンゾ複素環誘導体
ES2260316T3 (es) 2000-12-27 2006-11-01 Janssen Pharmaceutica N.V. Derivados de quinazolina y quinolina 4-sustituidos que inhiben la farnesil transferasa.
PT1351954E (pt) * 2000-12-27 2006-09-29 Janssen Pharmaceutica Nv Derivados 4-heterociclil-quinolina e quinazolina inibidores da farnesil-transferase
EP1408971A4 (en) 2001-06-21 2006-01-25 Ariad Pharma Inc NEW QUINOLINES AND THEIR USES
CA2469275C (en) 2001-12-19 2011-09-06 Janssen Pharmaceutica N.V. 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
AU2003223970B2 (en) 2002-03-22 2008-03-06 Janssen Pharmaceutica N.V. Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
EP1497295B1 (en) 2002-04-15 2006-08-16 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
US7517890B2 (en) 2003-11-20 2009-04-14 Children's Hospital Medical Center GTPase inhibitors and methods of use
SG150533A1 (en) * 2003-11-20 2009-03-30 Janssen Pharmaceutica Nv 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors
WO2005089502A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005089496A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
WO2005089518A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Uch-l1 expression and cancer therapy
WO2005089504A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
EP1920048A4 (en) 2005-07-29 2009-12-09 Childrens Hosp Medical Center GTASE INHIBITORS AND USE METHOD AND CRYSTAL STRUCTURE OF RAC-1 GTASE
EP2545919A1 (en) 2005-12-23 2013-01-16 Link Medicine Corporation Treatment of synucleinopathies
WO2008147788A1 (en) * 2007-05-23 2008-12-04 Allergan, Inc. Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
EP2138844B1 (en) 2008-06-26 2012-04-25 SpheroTec GmbH Method for testing the response of cells to exposures with therapeutics
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
JP2012508768A (ja) * 2008-11-13 2012-04-12 リンク・メディスン・コーポレーション アザキノリノン誘導体及びその使用
US9980942B2 (en) 2012-05-02 2018-05-29 Children's Hospital Medical Center Rejuvenation of precursor cells
MY189505A (en) 2012-10-16 2022-02-16 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of roryt
PE20151203A1 (es) 2012-10-16 2015-08-31 Janssen Pharmaceutica Nv MODULADORES DE QUINOLINILO UNIDOS A FENILO DE ROR-GAMMA-t
HK1213250A1 (zh) 2012-10-16 2016-06-30 Janssen Pharmaceutica, N.V. RORγT的雜芳基連接的喹啉基調節劑
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
AU2014334619A1 (en) 2013-10-15 2016-04-21 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORyt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
CA2927182A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Quinolinyl modulators of ror.gamma.t
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
TWI621437B (zh) 2015-08-17 2018-04-21 庫拉腫瘤技術股份有限公司 以法呢基轉移酶（farnesyltransferase）抑制劑治療癌症病患之方法
US20190119758A1 (en) 2016-04-22 2019-04-25 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
LT3534885T (lt) 2016-11-03 2021-07-12 Kura Oncology, Inc. Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui
US9956215B1 (en) 2017-02-21 2018-05-01 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2018156609A1 (en) 2017-02-21 2018-08-30 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
CN111182899A (zh) 2017-08-07 2020-05-19 库拉肿瘤学公司 使用法尼基转移酶抑制剂治疗癌症的方法
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
TW202031259A (zh) 2018-11-01 2020-09-01 美商庫拉腫瘤技術股份有限公司 以法尼基轉移酶(farnesyltransferase)抑制劑治療癌症之方法
WO2020180663A1 (en) 2019-03-01 2020-09-10 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US20220143006A1 (en) 2019-03-15 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
KR20210144778A (ko) 2019-03-29 2021-11-30 쿠라 온콜로지, 인크. 파르네실트랜스퍼라제 억제제를 사용한 편평 세포 암종의 치료 방법
TW202102218A (zh) 2019-04-01 2021-01-16 美商庫拉腫瘤技術股份有限公司 以法呢基(farnesyl)轉移酶抑制劑治療癌症的方法
WO2020223583A1 (en) 2019-05-02 2020-11-05 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
EP4013402B1 (en) 2019-08-16 2024-11-06 Children's Hospital Medical Center Cdc-42 inhibitors for use in the treatment of age-related depression, sarcopenia or frailty

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141851A (en) * 1990-04-18 1992-08-25 Board Of Regents, The University Of Texas System Isolated farnesyl protein transferase enzyme
US6083917A (en) * 1990-04-18 2000-07-04 Board Of Regents, The University Of Texas System Methods and compositions for the identification, characterization and inhibition of farnesyltransferase
US5602184A (en) 1993-03-03 1997-02-11 The United States Of America As Represented By Department Of Health And Human Services Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
EA000710B1 (ru) * 1995-12-08 2000-02-28 Жансен Фармасетика Н.В. (имидазол-5-ил)метил-2-хинолиноновые производные, ингибирующие фарнезилпротеин-трансферазу
AU714560B2 (en) * 1996-04-15 2000-01-06 Trustees Of The University Of Pennsylvania, The Sensitization of cells to radiation and chemotherapy
EP0918771A4 (en) * 1996-07-15 2001-02-07 Bristol Myers Squibb Co THIADIOXOBENZODIAZEPINES FOR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
PL193464B1 (pl) 1998-07-06 2007-02-28 Janssen Pharmaceutica Nv Zastosowanie inhibitora białkowej transferazy farnezylowej
EA200100766A1 (ru) * 1999-02-11 2002-02-28 Пфайзер Продактс Инк. Хинолин-2-он замещенные гетероарильные производные, используемые в качестве противоопухолевых агентов

Also Published As

Publication number Publication date
BR9911861A (pt) 2001-03-20
NO328178B1 (no) 2009-12-28
EE04582B1 (et) 2006-02-15
WO2000001411A1 (en) 2000-01-13
MY126519A (en) 2006-10-31
SK19862000A3 (sk) 2001-12-03
TW586937B (en) 2004-05-11
NO20010082D0 (no) 2001-01-05
CN1152716C (zh) 2004-06-09
CZ20004777A3 (en) 2001-05-16
AU762423B2 (en) 2003-06-26
CA2336624A1 (en) 2000-01-13
SI1094839T1 (en) 2003-12-31
IL140721A0 (en) 2002-02-10
PL193464B1 (pl) 2007-02-28
AP2001002057A0 (en) 2001-03-31
NO20010082L (no) 2001-01-05
CN1311692A (zh) 2001-09-05
ATE238811T1 (de) 2003-05-15
ID26987A (id) 2001-02-22
ES2199579T3 (es) 2004-02-16
HRP20000903A2 (en) 2001-12-31
PL347979A1 (en) 2002-05-06
HU229076B1 (en) 2013-07-29
TR200003879T2 (tr) 2007-01-22
DK1094839T3 (da) 2003-08-18
HK1034451A1 (en) 2001-10-26
DE69907461D1 (de) 2003-06-05
JP4530537B2 (ja) 2010-08-25
HUP0103689A3 (en) 2003-01-28
KR100591603B1 (ko) 2006-06-20
CA2336624C (en) 2008-10-21
DE69907461T2 (de) 2004-02-19
AU4780599A (en) 2000-01-24
KR20010052770A (ko) 2001-06-25
EP1094839A1 (en) 2001-05-02
CZ300968B6 (cs) 2009-09-30
PT1094839E (pt) 2003-09-30
EA003877B1 (ru) 2003-10-30
SK284723B6 (sk) 2005-10-06
BG64941B1 (bg) 2006-10-31
EA200100111A1 (ru) 2001-06-25
EP1094839B1 (en) 2003-05-02
AP1599A (en) 2006-04-27
HUP0103689A2 (hu) 2002-02-28
JP2002519389A (ja) 2002-07-02
IL140721A (en) 2008-11-26
EE200000794A (et) 2002-06-17
US6545020B1 (en) 2003-04-08

Similar Documents

Publication Publication Date Title
BG105108A (bg) Инхибитори на фарнезил протеин трансфераза с in vivo чувствителност към радиоактивно облъчване
MY120841A (en) Methods of inducing cancer cell death and tumor regression
NO20012774D0 (no) Preparat og metode hvor det gjöres bruk av eteriske planteoljer
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
GEP20012500B (en) Inhibitors of Protein Farnesyl Transferase
ATE425749T1 (de) Behandlung von mit her-2/neu-uberexprimierung einhergehendem krebs
NO20014662L (no) Fremgangsmåter og preparater for behandling av faste tumorer
WO1998033491A3 (en) Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase
SI1255537T1 (sl) Inhibitorji farnezil protein transferaze za zdravljenje raka dojk
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
EP2258702A3 (en) Purified compositions of 10-Propargyl-10-Deazaaminopterin and method of using same in the treatment of tumors
IL125776A (en) Use of a cimicifuga racemosa extract for the manufacture of a drug for treating estrogen-dependent tumors
HK1052870A1 (zh) 诱导癌细胞死亡和肿瘤消退的方法
PT1076561E (pt) Terapia de combinacao para o tratamento de tumores
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
EG24180A (en) Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer
MD798G2 (ro) Metoda de tratament a cancerului mamar
RU95107493A (ru) Способ лечения опухолей паренхиматозных органов
WO2000037065A3 (en) Endocrine therapy for breast cancer: combined treatment with tamoxifen plus alkyl pcdfs
NZ509646A (en) Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties
IL164356A (en) Use of alpha- bromo or alpha-chloro acryloyl distamycin derivatives in the preparation of medicaments for treating cancer
ECSP982800A (es) Metodos para el tratamiento de enfermedades proliferativas
CY1107256T1 (el) Χημειοθεραπεια συνδυασμου
MX9703208A (es) Tetra-y pentapeptidos substituidos inhibidores de proteina; farnesil transferasa.
UA29212A (uk) Спосіб лікування раку тіла матки iii-iv стадії